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Myeloma-derived macrophage inhibitory
factor regulates bone marrow stromal
cell-derived IL-6 via c-MYC
Rachel E. Piddock1, Christopher R. Marlein1, Amina Abdul-Aziz1, Manar S. Shafat1, Martin J. Auger2,
Kristian M. Bowles1,2*† and Stuart A. Rushworth1*†
Abstract: Multiple myeloma (MM) remains an incurable malignancy despite the recent advancements in its
treatment. The protective effects of the niche in which it develops has been well documented; however, little has
been done to investigate the MM cell’s ability to ‘re-program’ cells within its environment to benefit disease
progression. Here, we show that MM-derived macrophage migratory inhibitory factor (MIF) stimulates bone marrow
stromal cells to produce the disease critical cytokines IL-6 and IL-8, prior to any cell-cell contact. Furthermore, we
provide evidence that this IL-6/8 production is mediated by the transcription factor cMYC. Pharmacological
inhibition of cMYC in vivo using JQ1 led to significantly decreased levels of serum IL-6—a highly positive
prognostic marker in MM patients.
Conclusions: Our presented findings show that MM-derived MIF causes BMSC secretion of IL-6 and IL-8 via BMSC
cMYC. Furthermore, we show that the cMYC inhibitor JQ1 can reduce BMSC secreted IL-6 in vivo, irrespective of
tumor burden. These data provide evidence for the clinical evaluation of both MIF and cMYC inhibitors in the
treatment of MM.
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Despite significant recent advancements made in the
treatment of multiple myeloma (MM), relapse remains
inevitable and the disease presently remains incurable.
This is attributable, in part, to the highly protective na-
ture of the BM micro-environment niche in which the
malignant plasma cells proliferate. Macrophage migra-
tory inhibitory factor (MIF) is a cytokine associated with
various roles [1] and is rapidly developing a pro-tumoral
identity [2]. Elevated MIF levels are described in MM
and have been implicated in MM bone marrow homing
and chemotherapy resistance [3]; however, the adaptive
effect that MM-derived MIF has on the tumor micro-
environment is not yet defined. Here, we investigate the
function of MM-derived MIF in the MM microenviron-
ment by examining its effects on bone marrow stromal
cells (BMSC).
We and others have found that MM cells have signifi-
cantly elevated MIF gene expression and secreted pro-
tein levels [3] (Additional file 1: Figure S1). MIF KD
resulted in lower MM proliferation in BMSC co-culture
(Additional file 1: Figure S2C) alongside reduced tumor
burden and improved overall survival in vivo (Fig. 1a, b).
To investigate the effects of MIF secretion by MM on its
microenvironment, we used cytokine arrays to establish
if cytokine changes occur when MM cells are cultured
with primary BMSC. Elevated levels of IL-6/8 were de-
tected in co-culture experiments when compared with ei-
ther BMSC or MM monoculture arrays (Fig. 1c, d); no MIF
was detected in BMSC cultured alone. Cytokine array
analysis of the supernatant from MIF-stimulated BMSCs
confirmed this IL-6/IL-8 secretion (Fig. 1e, f) and was
quantified via ELISA (Additional file 2) in Fig. 1g. Pre-
treatment of BMSC with the MIF inhibitor ISO-1 signifi-
cantly reduced the MIF induction of IL-6/IL-8 by BMSC
(Fig. 1h). BMSC expressed all three known receptors for
MIF (CXCR4, CXCR2 and CD74); however, only blocking
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Fig. 1 MM derived MIF is pro-tumoral and drives BMSC IL-6 and IL-8. 1 × 106 MM.1S-luc cells (ShE control n = 10, and ShMIF n = 7) were injected
via the tail vein of 6–8-week-old NSG mice. a Mice were monitored weekly by bioluminescent imaging. b Kaplan-Meier curve showing survival,
analyzed using Mantel Cox regression. c Representative (n = 3) Human XL cytokine array output after a 24-h incubation in either mono or co-culture,
cell supernatant was used for analysis. d Graphical representation of c—values for BMSC and MM monoculture intensities were added together and
were analyzed against co-culture experiment signal intensity using HL++ image software which show differences in several key cytokines. e, f BMSC
were stimulated with 100 ng/mL of human recombinant MIF and incubated for 24 h; supernatant was used for assay. Representative (n = 3) image of
cytokine array (e) and subsequent graphical representation (f) of analysis using HL++ software. g Primary BMSC (n = 4) were stimulated with 100 ng/mL
recombinant human MIF for 6 h after which IL-6 and IL-8 protein excretion was analyzed by ELISA. h Primary BMSC (n = 4) were incubated with/
without 10μg ISO-1 and then stimulated with 100 ng/mL recombinant human MIF for 6 h. IL-6 and IL-8 transcriptional levels were then
analyzed by RT-PCR
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CD74 inhibited MIF-Induced IL6/8 (Additional file 1:
Figure S3A&B).
An inhibitor panel was used to screen for potential
pathways responsible for MIF-induced BMSC-derived
IL-6/IL-8 expression, and we found that JQ1 inhibited
MIF induced IL-6 and IL-8 (Fig. 2a, b) mRNA in BMSC.
We then determined if JQ1 could regulate BMSC pro-
tumoral interleukin production in-vivo. Although BMSC
are often cyto-protective in the context of anti-MM
therapy, others have observed that the sensitivity of MM
cell lines to JQ1 was unchanged by the presence of HS-5
[4]. Following MM engraftment (Fig. 2d), mice were ran-
domized and treated for 5 days with I.P injections of
50 mg/kg JQ1 or alternatively vehicle control. Under
7 days of treatment with JQ1 was predicted to have no
measurable effect on tumor burden [4] and was selected
to control for the effects of tumor burden on MM-MIF
secretion and subsequent BMSC IL-6 expression. We
found no difference in MM burden between groups
(Fig. 2d, f ). Nevertheless, murine IL-6 was signifi-
cantly reduced in the JQ1-treated animals (carrying
human MM) compared to control animals (Fig. 2e).
Despite MIF’s association with hematological malig-
nancies, previous work has focused on the effects of
MIF on the malignant cells rather than the supportive
cells of the microenvironment [3]. Here, we show that
MM-derived MIF is pro-tumoral through induction of
BMSC-derived IL-6/8. IL-6 is central to MM
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Fig. 2 MM-derived MIF regulates bone marrow stromal cell-derived IL-6 and IL-8 via cMYC. a, b BMSC cells were pretreated with various drugs
(bortezomib 10 nM, PS341 100 nM, Lenolidiomide 500 nM, JNKV 10uM, and JQ1 500 nM) for 30 mins and then activated with MIF for 2 h. RNA
was extracted, and transcriptional levels of IL-6 (a) or IL-8 (b) was analyzed. c Schematic showing JQ1 in vivo experiment. 1 × 106 U266 cells were
injected via the tail vein of NGS mice (n = 8). Following a 2-week engraftment period, mice were treated with 50 mg/kg JQ1 or vehicle control
daily for 5 days, after which all mice were sacrificed. d Mice were monitored pre and post treatment with JQ1 by bioluminescent imaging which
was quantified (f) by ImageJ densitometry. e ELISA data showing murine IL-6 serum concentration following JQ1 treatment. Baseline levels of
murine IL-6 were non-detectable in mice without MM
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pathogenesis and primarily comes from the BMSC in
the tumor micro-environment [5]. Here, we place IL-6
downstream of MIF-induced BMSC activation [6, 7]. IL-
8 expression in BMSC, which has been shown to parallel
MM disease progression [8] and positively influence os-
teoclastogenesis in MM [9], was increased in BMSC in
response to MIF. Furthermore, the BET-bromodomain
inhibitor JQ1 significantly decreased IL-6/8 secretion in
MIF-stimulated BMSC. In vivo use of JQ1 significantly
reduced levels of murine IL-6 in the serum [5, 10, 11].
Taken together, this suggests that JQ1 is exerting anti-
MM activity, in part, through a direct effect on BMSC
via the inhibition of BMSC IL-6 (and IL-8) synthesis.
This in turn could explain why BMSC do not appear to
offer MM protection from JQ1 therapy.
Additional files
Additional file 1: Figure S1. (A) Relative transcriptional levels of MIF
expression in B cells, T cells, non-malignant plasma cells and CD138+
purified primary MM cells were normalized to Beta-Actin (n = 5). (B) MIF
ELISA data showing the increase in MIF extracellular protein levels in
CD138+ purified primary MM cells and MM cell lines in comparison to
other cell types (n = 5). Figure S2. (A) MM.1 s cells were transduced with
lentivirus targeted to MIF or control shRNA for 96 h. RNA was extracted
and MIF mRNA expression was analyzed via RT-PCR to confirm KD. (B)
Cells described in (A) were cultured for 24 h in fresh media after which
the supernatant was analyzed for MIF via ELISA. (C) MM.1S MIF KD cells
were co-cultured with primary BMSC for 96 h, after which MM cells were
analyzed using Cell Titre Glo (CTG), normalized to a ShE control. Figure S3.
(A) BMSC from MM patients was analyzed for CXCR4, CXCR2 and CD74
using flow cytometry and compared to isotype control. (B) BMSC were
preincubated with either AMD3100 (10 μM), SB225002 (100 nM) and
anti-CD74 (10 μg/ml). BMSC were then stimulated with recombinant
MIF (100 ng/ml) for 2 h. RNA was extracted and analyzed for IL-6
and IL-8 expression using Real-time PCR. (PPTX 178 kb)
Additional file 2: Supplementary methods. Methods section. (DOCX 19 kb)
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